Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Annals of the Rheumatic Diseases|November 10, 2020
Efficacy and safety of abatacept in active primary Sjögren's syndrome: results of a phase III, randomised, placebo-controlled trialAlan N Baer, Jacques-Eric Gottenberg, E William St Clair, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 4, 2017
Antiviral Activity, Safety, and Exposure-Response Relationships of GSK3532795, a Second-Generation Human Immunodeficiency Virus Type 1 Maturation Inhibitor, Administered as Monotherapy or in Combination With Atazanavir With or Without Ritonavir in a Phase 2a Randomized, Dose-Ranging, Controlled Trial (AI468002)Carey Hwang, Dirk Schürmann, Christian Sobotha, et al.
The Journal of Antimicrobial Chemotherapy|October 17, 2013
Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068Nannan Zhou, Beata Nowicka-Sans, Brian McAuliffe, et al.
The Journal of Infectious Diseases|August 17, 2012
Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjectsRichard E Nettles, Dirk Schürmann, Li Zhu, et al.
The Lancet. HIV|January 15, 2016
Efficacy, safety, bone and metabolic effects of HIV nucleoside reverse transcriptase inhibitor BMS-986001 (AI467003): a phase 2b randomised, controlled, partly blinded trialSamir K Gupta, Grace A McComsey, John Lombaard, et al.
Food & Function|July 14, 2022
Inhibitory effect of selected Indian honey on colon cancer cell growth by inducing apoptosis and targeting the β-catenin/Wnt pathwayNeeladrisingha Das, Neelanjana Ray, Abhinandan R Patil, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|May 13, 2011
Enhanced phosphatase activity attenuates α-synucleinopathy in a mouse modelKang-Woo Lee, Walter Chen, Eunsung Junn, et al.
The Lancet. Rheumatology|January 30, 2024
Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS): development and validation of a novel outcome measureSuzanne Arends, Liseth de Wolff, Jolien F van Nimwegen, et al.
The Journal of Infectious Diseases|April 22, 2017
Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral TherapyCynthia L Gay, Ronald J Bosch, Justin Ritz, et al.
Antimicrobial Agents and Chemotherapy|May 2, 2012
In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068Beata Nowicka-Sans, Yi-Fei Gong, Brian McAuliffe, et al.
Pageof 4